Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Recommendation of “Moderate Buy” by Brokerages

Denali Therapeutics Inc. (NASDAQ:DNLI) has been assigned a consensus recommendation of “Moderate Buy” from the seventeen brokerages that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, thirteen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $35.0833.

Several brokerages have commented on DNLI. Wedbush restated an “outperform” rating and set a $26.00 target price on shares of Denali Therapeutics in a report on Monday, July 13th. Leerink Partners cut their price objective on shares of Denali Therapeutics from $40.00 to $35.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 22nd. JPMorgan Chase & Co. started coverage on shares of Denali Therapeutics in a research note on Monday, July 13th. They issued an “overweight” rating and a $29.00 target price for the company. Stifel Nicolaus set a $41.00 price objective on Denali Therapeutics in a report on Monday, June 22nd. Finally, The Goldman Sachs Group raised their price objective on Denali Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, March 26th.

Institutional Trading of Denali Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Headlands Technologies LLC acquired a new stake in Denali Therapeutics in the 2nd quarter valued at about $26,000. Johnson Financial Group Inc. acquired a new position in shares of Denali Therapeutics in the third quarter valued at approximately $29,000. State of Wyoming acquired a new stake in shares of Denali Therapeutics during the second quarter worth $29,000. Fifth Third Bancorp bought a new stake in Denali Therapeutics in the 1st quarter valued at about $55,000. Finally, Aster Capital Management DIFC Ltd bought a new position in Denali Therapeutics during the 4th quarter worth $57,000. Institutional investors and hedge funds own 92.92% of the company’s stock.

Denali Therapeutics Price Performance

DNLI opened at $23.29 on Tuesday. The stock has a market cap of $3.70 billion, a P/E ratio of -8.09 and a beta of 0.96. Denali Therapeutics has a 12 month low of $12.58 and a 12 month high of $27.30. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 0.01. The company has a fifty day simple moving average of $22.21 and a 200 day simple moving average of $20.58.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Thursday, May 7th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.04. During the same period last year, the firm earned ($0.78) earnings per share. On average, research analysts expect that Denali Therapeutics will post -2.74 EPS for the current year.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.